Hiroshi Komura

Dr. Hiroshi Komura

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HKHiroshi Komura
Hiroshi Komura
RWReiko Watanabe
Reiko Watanabe
KMKenji Mizuguchi
Kenji Mizuguchi
Drug discovery and development are aimed at identifying new chemical molecular entities (NCEs) with desirable pharmacokinetic profiles for high therapeutic efficacy. The plasma concentrations of NCEs are a biomarker of their efficacy and are governed by pharmacokinetic processes such as absorption, distribution, metabolism, and excretion (ADME). Poor ADME properties of NCEs are a major cause of attrition in drug development. ADME screening is used to identify and optimize lead compounds in the drug discovery process. Computational models predicting ADME properties have been developed with evolving model-building technologies from a simplified relationship between ADME endpoints and physicochemical properties to machine learning, including support vector machines, random forests, and convolution neural networks. Recently, in the field of in silico ADME research, there has been a shift toward evaluating the in vivo parameters or plasma concentrations of NCEs instead of using predictive results to guide chemical structure design. Another research hotspot is the establishment of a computational prediction platform to strengthen academic drug discovery. Bioinformatics projects have produced a series of in silico ADME models using free software and open-access databases. In this review, we introduce prediction models for various ADME parameters and discuss the currently available academic drug discovery platforms.

13 November 2013 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
HKHiroshi Komura
Hiroshi Komura
INIkuo Nomura
Ikuo Nomura
KKKazuo Kitamura
Kazuo Kitamura
KKKenji Kuwasako
Kenji Kuwasako
Johji KatoJohji Kato
Johji Kato
Background: An epidemiological approach to preventing the development or progression of chronic kidney disease (CKD) is necessary, while few effective preventive measures are currently available. We conducted a community-based, cohort study to identify the factors associated with the development of CKD in the general population. Methods: We examined 1876 local residents of a Japanese community who had an annual health check-up and, of those, 1506 residents judged not to have CKD (473 men and 1033 women) were followed for the development of CKD over 10 years. Results: The numbers of male and female residents who developed CKD during the follow-up period were 167 (35.3%) and 299 (28.9%), respectively. As compared to those without CKD development, the residents who developed CKD were older, and had a higher body mass index (BMI), systolic blood pressure, and creatinine in both genders. The rate of CKD development in obese female residents was higher than in non-obese women, but such a difference was not noted in male residents. In addition to age and serum creatinine, we identified BMI as an independently significant factor for the development of CKD in women, but not in men. Conclusions: Increased BMI is a significant risk factor for the development of CKD in women, and there seems to be a gender difference in the association between increased BMI and the development of CKD in the general population.

1 May 2021 in Drug Discovery Today
Verified
Journal Article
Open access
HKHiroshi Komura
Hiroshi Komura
RWReiko Watanabe
Reiko Watanabe
HKHitoshi Kawashima
Hitoshi Kawashima
RORikiya Ohashi
Rikiya Ohashi
MKMasataka Kuroda
Masataka Kuroda
KMKenji Mizuguchi
Kenji Mizuguchi
A novel framework for a public-private (PP) partnership was established by a national initiative of the Development of a Drug Discovery Informatics System, supported by the Japan Agency for Medical Research and Development (AMED). This informatics PP partnership consortium comprised private and public sectors. A database of pharmacokinetic (PK) and cardiotoxic properties was developed, with considerable expansion after integrating proprietary data from private-sector members. This database led to robust in silico prediction models with higher performance than those from the original database. This partnership is a unique example worldwide and could substantially strengthen drug discovery capabilities in both sectors.